Browse by Research Team

Article

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Borchmann, P., Ferdinandus, J., Schneider, G., Moccia, A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J.M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Scholl, S., Topp, M.S., Jung, W., Vucinic, V., Beck, H.J., Kerkhoff, A., Unger, B., Rank, A., Schroers, R., zum Büschenfelde, C.M., de Wit, M., Trautmann-Grill, K., Kamper, P., Molin, D., Kreissl, S., Kaul, H., von Tresckow, B., Borchmann, S., Behringer, K., Fuchs, M., Rosenwald, A., Klapper, W., Eich, H.T., Baues, C., Zomas, A., Hallek, M., Dietlein, M., Kobe, C. and Diehl, V.
Lancet 404 (10450): 341-352. 27 July 2024

JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
Redmer, T., Raigel, M., Sternberg, C., Ziegler, R., Probst, C., Lindner, D., Aufinger, A., Limberger, T., Trachtova, K., Kodajova, P., Högler, S., Schlederer, M., Stoiber, S., Oberhuber, M., Bolis, M., Neubauer, H.A., Miranda, S., Tomberger, M., Harbusch, N.S., Garces de Los Fayos Alonso, I., Sternberg, F., Moriggl, R., Theurillat, J.P., Tichy, B., Bystry, V., Persson, J.L., Mathas, S., Aberger, F., Strobl, B., Pospisilova, S., Merkel, O., Egger, G., Lagger, S. and Kenner, L.
Molecular Cancer 23 (1): 114. 29 May 2024

High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial.
Schorb, E., Isbell, L.K., Kerkhoff, A., Mathas, S., Braulke, F., Egerer, G., Röth, A., Schliffke, S., Borchmann, P., Brunnberg, U., Kroschinsky, F., Möhle, R., Rank, A., Wellnitz, D., Kasenda, B., Pospiech, L., Wendler, J., Scherer, F., Deckert, M., Henkes, E., von Gottberg, P., Gmehlin, D., Backenstraß, M., Jensch, A., Burger-Martin, E., Grishina, O., Fricker, H., Malenica, N., Orbán, A., Duyster, J., Ihorst, G., Finke, J. and Illerhaus, G.
Lancet Haematology 11 (3): e196-e205. March 2024

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial.
Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A.S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J., Greil, R., Feuring-Buske, M., Markova, J., Rüffer, J.U., Kobe, C., Eich, H.T., Baues, C., Fuchs, M., Borchmann, P. and Behringer, K.
Annals of Oncology 35 (3): 276-284. March 2024

A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
Habringer, S., Demel, U.M., Fietz, A.K., Lammer, F., Schroers, R., Hofer, S., Bairey, O., Braess, J., Meier-Stiegen, A.S., Stuhlmann, R., Schmidt-Hieber, M., Hoffmann, J., Zinngrebe, B., Kaiser, U., Reimer, P., Möhle, R., Fix, P., Höffkes, H.G., Langenkamp, U., Büschenfelde, C.M.Z., Hopfer, O., Stoltefuß, A., La Rosée, P., Blasberg, H., Jordan, K., Kaun, S., Meurer, A., Unteroberdörster, M., von Brünneck, A.C., Capper, D., Heppner, F.L., Chapuy, B., Janz, M., Schwartz, S., Konietschke, F., Vajkoczy, P., Korfel, A. and Keller, U.
European Journal of Cancer 196 : 113436. January 2024

Transcriptional reprogramming by mutated IRF4 in lymphoma.
Schleussner, N., Cauchy, P., Franke, V., Giefing, M., Fornes, O., Vankadari, N., Assi, S.A., Costanza, M., Weniger, M.A., Akalin, A., Anagnostopoulos, I., Bukur, T., Casarotto, M.G., Damm, F., Daumke, O., Edginton-White, B., Gebhardt, J.C.M., Grau, M., Grunwald, S., Hansmann, M.L., Hartmann, S., Huber, L., Kärgel, E., Lusatis, S., Noerenberg, D., Obier, N., Pannicke, U., Fischer, A., Reisser, A., Rosenwald, A., Schwarz, K., Sundararaj, S., Weilemann, A., Winkler, W., Xu, W., Lenz, G., Rajewsky, K., Wasserman, W.W., Cockerill, P.N., Scheidereit, C., Siebert, R., Küppers, R., Grosschedl, R., Janz, M., Bonifer, C. and Mathas, S.
Nature Communications 14 (1): 6947. 7 November 2023

Broadening the phenotypic and molecular spectrum of FINCA syndrome: Biallelic NHLRC2 variants in 15 novel individuals.
Sczakiel, H.L., Zhao, M., Wollert-Wulf, B., Danyel, M., Ehmke, N., Stoltenburg, C., Damseh, N., Al-Ashhab, M., Balci, T.B., Osmond, M., Andrade, A., Schallner, J., Porrmann, J., McDonald, K., Liao, M., Oppermann, H., Platzer, K., Dierksen, N., Mojarrad, M., Eslahi, A., Bakaeean, B., Calame, D.G., Lupski, J.R., Firoozfar, Z., Seyedhassani, S.M., Mohammadi, S.A., Anwaar, N., Rahman, F., Seelow, D., Janz, M., Horn, D., Maroofian, R. and Boschann, F.
European Journal of Human Genetics 31 (8): 905-317. August 2023

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
Bonifacius, A., Lamottke, B., Tischer-Zimmermann, S., Schultze-Florey, R., Goudeva, L., Heuft, H.G., Arseniev, L., Beier, R., Beutel, G., Cario, G., Fröhlich, B., Greil, J., Hansmann, L., Hasenkamp, J., Höfs, M., Hundsdoerfer, P., Jost, E., Kafa, K., Kriege, O., Kröger, N., Mathas, S., Meisel, R., Nathrath, M., Putkonen, M., Ravens, S., Reinhardt, H.C., Sala, E., Sauer, M.G, Schmitt, C., Schroers, R., Steckel, N.K., Trappe, R.U., Verbeek, M., Wolff, D., Blasczyk, R., Eiz-Vesper, B. and Maecker-Kolhoff, B.
Journal of Clinical Investigation 133 (12): e163548. 15 June 2023

Mouse models of human multiple myeloma subgroups.
Winkler, W., Farré Díaz, C., Blanc, E., Napieczynska, H., Langner, P., Werner, M., Walter, B., Wollert-Wulf, B., Yasuda, T., Heuser, A., Beule, D., Mathas, S., Anagnostopoulos, I., Rosenwald, A., Rajewsky, K. and Janz, M.
Proceedings of the National Academy of Sciences of the United States of America 120 (10): e2219439120. 7 March 2023

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen, G.J.J.E., Baumgartner, F., Heider, M., Patra, U., Holz, M., Braune, J., Kaiser, M., Schäffer, I., Bamopoulos, S.A., Ramberger, E., Murgai, A., Ng, Y.L.D., Demel, U.M., Laue, D., Liebig, S., Krüger, J., Janz, M., Nogai, A., Schick, M., Mertins, P., Müller, S., Bassermann, F., Krönke, J., Keller, U. and Wirth, M.
Blood Advances 7 (4): 469-481. 28 February 2023

Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin Lymphoma: final analysis of the randomized german Hodgkin study group phase II NIVAHL trial.
Bröckelmann, P.J., Bühnen, I., Meissner, J., Trautmann-Grill, K., Herhaus, P., Halbsguth, T.V., Schaub, V., Kerkhoff, A., Mathas, S., Bormann, M., Dickhut, A., Kaul, H., Fuchs, M., Kobe, C., Baues, C., Borchmann, P., Engert, A. and von Tresckow, B.
Journal of Clinical Oncology 41 (6): 1193-1199. 20 February 2023

Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas.
Lopez, C., Schleussner, N., Bernhart, S.H., Kleinheinz, K., Sungalee, S., Sczakiel, H.L., Kretzmer, H., Toprak, U.H., Glaser, S., Wagener, R., Ammerpohl, O., Bens, S., Giefing, M., Sanchez, J.C.G., Apic, G., Hubschmann, D., Janz, M., Kreuz, M., Mottok, A., Müller, J.M., Seufert, J., Hoffmann, S., Korbel, J.O., Russell, R.B., Schule, R., Trumper, L., Klapper, W., Radlwimmer, B., Lichter, P., Kuppers, R., Schlesner, M., Mathas, S. and Siebert, R.
Haematologica 108 (2): 543-554. 1 February 2023

A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency.
Fornes, O., Jia, A., Kuehn, H.S., Min, Q., Pannicke, U., Schleussner, N., Thouenon, R., Yu, Z., de Los Angeles Astbury, M., Biggs, C.M., Galicchio, M., Garcia-Campos, J.A., Gismondi, S., Gonzalez Villarreal, G., Hildebrand, K.J., Hönig, M., Hou, J., Moshous, D., Pittaluga, S., Qian, X., Rozmus, J., Schulz, A.S., Staines-Boone, A.T., Sun, B., Sun, J., Uwe, S., Venegas-Montoya, E., Wang, W., Wang, X., Ying, W., Zhai, X., Zhou, Q., Akalin, A., André, I., Barth, T.F.E., Baumann, B., Brüstle, A., Burgio, G., Bustamante, J.C., Casanova, J.L., Casarotto, M.G., Cavazzana, M., Chentout, L., Cockburn, I.A., Costanza, M., Cui, C., Daumke, O., Del Bel, K.L., Eibel, H., Feng, X., Franke, V., Gebhardt, J.C.M., Götz, A., Grunwald, S., Hoareau, B., Hughes, T.R., Jacobsen, E.M., Janz, M., Jolma, A., Lagresle-Peyrou, C., Lai, N., Li, Y., Lin, S., Lu, H.Y., Lugo-Reyes, S.O., Meng, X., Möller, P., Moreno-Corona, N., Niemela, J.E., Novakovsky, G., Perez-Caraballo, J.J., Picard, C., Poggi, L., Puig-Lombardi, M.E., Randall, K.L., Reisser, A., Schmitt, Y., Seneviratne, S., Sharma, M., Stoddard, J., Sundararaj, S., Sutton, H., Tran, L.Q., Wang, Y., Wasserman, W.W., Wen, Z., Winkler, W., Xiong, E., Yang, A.W.H., Yu, M., Zhang, L., Zhang, H., Zhao, Q., Zhen, X., Enders, A., Kracker, S., Martinez-Barricarte, R., Mathas, S., Rosenzweig, S.D., Schwarz, K., Turvey, S.E. and Wang, J.Y.
Science Immunology 8 (79): eade7953. January 2023

PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.
Garces de Los Fayos Alonso, I., Zujo, L., Wiest, I., Kodajova, P., Timelthaler, G., Edtmayer, S., Zrimšek, M., Kollmann, S., Giordano, C., Kothmayer, M., Neubauer, H.A., Dey, S., Schlederer, M., Schmalzbauer, B.S., Limberger, T., Probst, C., Pusch, O., Högler, S., Tangermann, S., Merkel, O., Schiefer, A.I., Kornauth, C., Prutsch, N., Zimmerman, M., Abraham, B., Anagnostopoulos, J., Quintanilla-Martinez, L., Mathas, S., Wolf, P., Stoiber, D., Staber, P.B., Egger, G., Klapper, W., Woessmann, W., Look, T.A., Gunning, P., Turner, S.D., Moriggl, R., Lagger, S. and Kenner, L.
Molecular Cancer 21 (1): 172. 31 August 2022

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
Jacob, A.S., Kaul, H., Fuchs, M., Gillessen, S., Kreissl, S., Pluetschow, A., Momotow, J., Schaub, V., Huettmann, A., Haenel, M., Zimmermann, A., Dierlamm, J., Meissner, J., Mathas, S., Martin, S., Engert, A., Hallek, M., Borchmann, P. and Lehmann, C.
Infection 50 (4): 925-932. August 2022

Differentiation of cerebral neoplasms with vessel size imaging (VSI).
Foda, A., Kellner, E., Gunawardana, A., Gao, X., Janz, M., Kufner, A., Khalil, A.A., Geran, R., Mekle, R., Fiebach, J.B. and Galinovic, I.
Clinical Neuroradiology 32 (1): 239-248. March 2022

Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.
Bishop, M.R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I., Rabitsch, W., Kwong, Y.L., Kersten, M.J, Minnema, M.C., Holte, H., Chan, E.H.L., Martinez-Lopez, J., Müller, A.M.S., Maziarz, R.T., McGuirk, J.P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., Del Corral, C., Andreola, G., Masood, A., Schuster, S.J., Jäger, U., Borchmann, P. and Westin, J.R.
New England Journal of Medicine 386 (7): 629-639. 17 February 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S., Bittner, A., Frick, M., Kase, J., Hoffmann, J., Trenker, C., Keller, U., Bogner, C., Hüttmann, A., Dürig, J., Janz, M., Mathas, S., Marks, R., Krohn, U., Na, I.K., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022

Aberrant expression of and cell death induction by engagement of the MHC-II chaperone CD74 in anaplastic large cell lymphoma (ALCL).
Wurster, K.D., Costanza, M., Kreher, S., Glaser, S., Lamprecht, B., Schleussner, N., Anagnostopoulos, I., Hummel, M., Jöhrens, K., Stein, H., Molina, A., Diepstra, A., Gillissen, B., Köchert, K., Siebert, R., Merkel, O., Kenner, L., Janz, M. and Mathas, S.
Cancers 13 (19): 5012. 1 October 2021

Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.
Liang, H.C., Costanza, M., Prutsch, N., Zimmerman, M.W., Gurnhofer, E., Montes-Mojarro, I.A., Abraham, B.J., Prokoph, N., Stoiber, S., Tangermann, S., Lobello, C., Oppelt, J., Anagnostopoulos, I., Hielscher, T., Pervez, S., Klapper, W., Zammarchi, F., Silva, D.A., Garcia, K.C., Baker, D., Janz, M., Schleussner, N., Fend, F., Pospíšilová, Š., Janiková, A., Wallwitz, J., Stoiber, D., Simonitsch-Klupp, I., Cerroni, L., Pileri, S., de Leval, L., Sibon, D., Fataccioli, V., Gaulard, P., Assaf, C., Knörr, F., Damm-Welk, C., Woessmann, W., Turner, S.D., Look, A.T., Mathas, S., Kenner, L. and Merkel, O.
Nature Communications 12 (1): 5577. 22 September 2021

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke, S., Bröckelmann, P.J., Iaccarino, I., Garcia-Marquez, M., Borchmann, S., Jochims, F., Kotrova, M., Pal, K., Brüggemann, M., Hartmann, E., Sasse, S., Kobe, C., Mathas, S., Soekler, M., Keller, U., Bormann, M., Zimmermann, A., Richter, J., Fuchs, M., von Tresckow, B., Borchmann, P., Schlößer, H., von Bergwelt-Baildon, M., Rosenwald, A., Engert, A. and Klapper, W.
Blood 136 (25): 2851-2863. 17 December 2020

B-cell-specific Myd88 L252P expression causes a premalignant gammopathy resembling IgM MGUS.
Schmidt, K., Sack, U., Graf, R., Winkler, W., Popp, O., Mertins, P., Sommermann, T., Kocks, C. and Rajewsky, K.
Frontiers in Immunology 11 : 602868. 1 December 2020

The transcription factor C/EBPβ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions.
Scholz, F., Grau, M., Menzel, L., Graband, A., Zapukhlyak, M., Leutz, A., Janz, M., Lenz, G., Rehm, A. and Höpken, U.E.
Proceedings of the National Academy of Sciences of the United States of America 117 (42): 26328-26339. 20 October 2020

PDGFA-associated protein 1 protects mature B lymphocytes from stress-induced cell death and promotes antibody gene diversification.
Delgado-Benito, V., Berruezo-Llacuna, M., Altwasser, R., Winkler, W., Sundaravinayagam, D., Balasubramanian, S., Caganova, M., Graf, R., Rahjouei, A., Henke, M.T., Driesner, M., Keller, L., Prigione, A., Janz, M., Akalin, A. and Di Virgilio, M.
Journal of Experimental Medicine 217 (10): e20200137. 5 October 2020

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky, F., Middeke, J.M., Janz, M., Lenz, G., Witzens-Harig, M., Bouabdallah, R., La Rosée, P., Viardot, A., Salles, G., Kim, S.J., Kim, T.M., Ottmann, O., Chromik, J., Quinson, A.M., von Wangenheim, U., Burkard, U., Berk, A. and Schmitz, N.
Investigational New Drugs 38 (5): 1472-1482. October 2020

Restriction of memory B cell differentiation at the germinal center B cell positive selection stage.
Toboso-Navasa, A., Gunawan, A., Morlino, G., Nakagawa, R., Taddei, A., Damry, D., Patel, Y., Chakravarty, P., Janz, M., Kassiotis, G., Brink, R., Eilers, M. and Calado, D.P.
Journal of Experimental Medicine 217 (7): e20191933. 6 July 2020

Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial.
Bröckelmann, P.J., Goergen, H., Keller, U., Meissner, J., Ordemann, R., Halbsguth, T.V., Sasse, S., Sökler, M., Kerkhoff, A., Mathas, S., Hüttmann, A., Bormann, M., Zimmermann, A., Mettler, J., Fuchs, M., von Tresckow, B., Baues, C., Rosenwald, A., Klapper, W., Kobe, C., Borchmann, P. and Engert, A.
JAMA Oncology 6 (6): 872-880. June 2020

Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
Edginton-White, B., Cauchy, P., Assi, S.A., Hartmann, S., Riggs, A.G., Mathas, S., Cockerill, P.N. and Bonifer, C.
Leukemia 33 (6): 1463-1474. June 2019

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.
von Hoff, L., Kärgel, E., Franke, V., McShane, E., Schulz-Beiss, K.W., Patone, G., Schleussner, N., Kolesnichenko, M., Hübner, N., Daumke, O., Selbach, M., Akalin, A., Mathas, S. and Scheidereit, C.
Blood 133 (13): 1489-1494. 28 March 2019

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
Schleussner, N., Merkel, O., Costanza, M., Liang, H.C., Hummel, F., Romagnani, C., Durek, P., Anagnostopoulos, I., Hummel, M., Jöhrens, K., Niedobitek, A., Griffin, P.R., Piva, R., Sczakiel, H.L., Woessmann, W., Damm-Welk, C., Hinze, C., Stoiber, D., Gillissen, B., Turner, S.D., Kaergel, E., von Hoff, L., Grau, M., Lenz, G., Dörken, B., Scheidereit, C., Kenner, L., Janz, M. and Mathas, S.
Leukemia 32 (9): 1994-2007. September 2018

Graded elevation of c-Jun in Schwann cells in vivo: gene dosage determines effects on development, remyelination, tumorigenesis, and hypomyelination.
Fazal, S.V., Gomez-Sanchez, J.A., Wagstaff, L.J., Musner, N., Otto, G., Janz, M., Mirsky, R. and Jessen, K.R.
Journal of Neuroscience 37 (50): 12297-12313. 13 December 2017

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer, D.A., Plütschow, A., Kreissl, S., Sökler, M., Hellmuth, J.C., Meissner, J., Mathas, S., Topp, M.S., Behringer, K., Klapper, W., Kuhnert, G., Dietlein, M., Kobe, C., Fuchs, M., Diehl, V., Engert, A. and Borchmann, P.
Lancet Oncology 18 (12): 1680-1687. December 2017

Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
Baras, N., Dahm, S., Haberland, J., Janz, M., Emrich, K., Kraywinkel, K. and Salama, A.
British Journal of Haematology 177 (2): 226-242. April 2017

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.
Wurster, K.D., Hummel, F., Richter, J., Giefing, M., Hartmann, S., Hansmann, M.L., Kreher, S., Köchert, K., Krappmann, D., Klapper, W., Hummel, M., Wenzel, S.S., Lenz, G., Janz, M., Dörken, B., Siebert, R. and Mathas, S.
Leukemia 31 (3): 602-613. March 2017

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma.
Du, J., Neuenschwander, M., Yu, Y., Däbritz, J.H.M., Neuendorff, N.R., Schleich, K., Bittner, A., Milanovic, M., Beuster, G., Radetzki, S., Specker, E., Reimann, M., Rosenbauer, F., Mathas, S., Lohneis, P., Hummel, M., Dörken, B., von Kries, J.P., Lee, S. and Schmitt, C.A.
Blood 129 (1): 71-81. 5 January 2017

Hodgkin lymphoma: pathology and biology.
Mathas, S., Hartmann, S. and Küppers, R.
Seminars in Hematology 53 (3): 139-147. July 2016

Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells.
Derudder, E., Herzog, S., Labi, V., Yasuda, T., Köchert, K., Janz, M., Villunger, A., Schmidt-Supprian, M. and Rajewsky, K.
Proceedings of the National Academy of Sciences of the United States of America 113 (18): 5065-5070. 3 May 2016

A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: dominant roles of p50 and p52 revealed by genome-wide analyses.
de Oliveira, K.A.P., Kaergel, E., Heinig, M., Fontaine, J.F., Patone, G., Muro, E.M., Mathas, S., Hummel, M., Andrade-Navarro, M.A., Hübner, N. and Scheidereit, C.
Genome Medicine 8 (1): 28. 17 March 2016

The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Doehner, H., Duyvene' de Wit, T., Eichinger, S., Fibbe, W., Green, T., de Haas, F., Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G. and Schuringa, J.J.
Haematologica 101 (2): 115-208. February 2016

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer, K., Goergen, H., Hitz, F., Zijlstra, J.M., Greil, R., Markova, J., Sasse, S., Fuchs, M., Topp, M.S., Soekler, M., Mathas, S., Meissner, J., Wilhelm, M., Koch, P., Lindemann, H.W., Schalk, E., Semrau, R., Kriz, J., Vieler, T., Bentz, M., Lange, E., Mahlberg, R., Hassler, A., Vogelhuber, M., Hahn, D., Mezger, J., Krause, S.W., Skoetz, N., Böll, B., von Tresckow, B., Diehl, V., Hallek, M., Borchmann, P., Stein, H., Eich, H. and Engert, A.
Lancet 385 (9976): 1418-1427. 11 April 2015

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
Weilemann, A., Grau, M., Erdmann, T., Merkel, O., Sobhiafshar, U., Anagnostopoulos, I., Hummel, M., Siegert, A., Hayford, C., Madle, H., Wollert-Wulf, B., Fichtner, I., Dörken, B., Dirnhofer, S., Mathas, S., Janz, M., Emre, N.C.T., Rosenwald, A., Ott, G., Lenz, P., Tzankov, A. and Lenz, G.
Blood 125 (1): 124-132. 1 January 2015

Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma.
Kreher, S., Bouhlel, M.A., Cauchy, P., Lamprecht, B., Li, S., Grau, M., Hummel, F., Köchert, K., Anagnostopoulos, I., Jöhrens, K., Hummel, M., Hiscott, J., Wenzel, S.S., Lenz, P., Schneider, M., Küppers, R., Scheidereit, C., Giefing, M., Siebert, R., Rajewsky, K., Lenz, G., Cockerill, P.N., Janz, M., Dörken, B., Bonifer, C. and Mathas, S.
Proceedings of the National Academy of Sciences of the United States of America 111 (42): E4513-E4522. 21 October 2014

Dendritic cell-mediated survival signals in Eμ-Myc B-cell lymphoma depend on the transcription factor C/EBPβ.
Rehm, A., Gätjen, M., Gerlach, K., Scholz, F., Mensen, A., Gloger, M., Heinig, K., Lamprecht, B., Mathas, S., Bégay, V., Leutz, A., Lipp, M., Dörken, B. and Höpken, U.E.
Nature Communications 5 : 5057. 30 September 2014

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.
Nogai, H., Wenzel, S.S., Hailfinger, S., Grau, M., Kaergel, E., Seitz, V., Wollert-Wulf, B., Pfeifer, M., Wolf, A., Frick, M., Dietze, K., Madle, H., Tzankov, A., Hummel, M., Dörken, B., Scheidereit, C., Janz, M., Lenz, P., Thome, M. and Lenz, G.
Blood 122 (13): 2242-2250. 26 September 2013

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer, M., Grau, M., Lenze, D., Wenzel, S.S., Wolf, A., Wollert-Wulf, B., Dietze, K., Nogai, H., Storek, B., Madle, H., Dörken, B., Janz, M., Dirnhofer, S., Lenz, P., Hummel, M., Tzankov, A. and Lenz, G.
Proceedings of the National Academy of Sciences of the United States of America 110 (30): 12420-12425. 23 July 2013

Structural insights into the mechanism of GTPase activation in the GIMAP family.
Schwefel, D., Arasu, B.S., Marino, S.F., Lamprecht, B., Köchert, K., Rosenbaum, E., Eichhorst, J., Wiesner, B., Behlke, J., Rocks, O., Mathas, S. and Daumke, O.
Structure 21 (4): 550-559. 2 April 2013

The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.
Calado, D.P., Sasaki, Y., Godinho, S.A., Pellerin, A., Köchert, K., Sleckman, B.P., de Alboran, I.M., Janz, M., Rodig, S. and Rajewsky, K.
Nature Immunology 13 (11): 1092-1100. November 2012

The tumour suppressor p53 is frequently nonfunctional in Sezary syndrome.
Lamprecht, B., Kreher, S., Moebs, M., Sterry, W., Doerken, B., Janz, M., Assaf, C. and Mathas, S.
British Journal of Dermatology 167 (2): 240-246. August 2012

Genomic loss of the putative tumor suppressor gene E2A in human lymphoma.
Steininger, A., Moebs, M., Ullmann, R., Koechert, K., Kreher, S., Lamprecht, B., Anagnostopoulos, I., Hummel, M., Richter, J., Beyer, M., Janz, M., Klemke, C.D., Stein, H., Doerken, B., Sterry, W., Schrock, E., Mathas, S. and Assaf, C.
Journal of Experimental Medicine 208 (8): 1585-1593. 1 August 2011

Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli, U.M., Ullrich, K., Stuehmer, T., Holien, T., Koechert, K., Holt, R.U., Bruland, O., Chatterjee, M., Nogai, H., Lenz, G., Shaughnessy, J.D., Mathas, S., Sundan, A., Bargou, R.C., Doerken, B., Borset, M. and Janz, M.
Oncogene 30 (28): 3198-3206. 14 July 2011

High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas.
Koechert, K., Ullrich, K., Kreher, S., Aster, J.C., Kitagawa, M., Joehrens, K., Anagnostopoulos, I., Jundt, F., Lamprecht, B., Zimber-Strobl, U., Stein, H., Janz, M., Doerken, B. and Mathas, S.
Oncogene 30 (15): 1831-1840. 14 April 2011

Repeat-element driven activation of proto-oncogenes in human malignancies.
Lamprecht, B., Bonifer, C. and Mathas, S.
Cell Cycle 9 (21): 4276-4281. November 2010

Common clonal origin of an acute B lymphoblastic leukemia and a Langerhans' cell sarcoma: evidence for hematopoietic plasticity.
Ratei, R., Hummel, M., Anagnostopoulos, I., Jaehne, D., Arnold, R., Doerken, B., Mathas, S., Thomas, B., Dudeck, O., Ludwig, W.D. and Stein, H.
Haematologica 95 (9): 1461-1466. September 2010

Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.
Lamprecht, B., Walter, K., Kreher, S., Kumar, R., Hummel, M., Lenze, D., Koechert, K., Bouhlel, M.A., Richter, J., Soler, E., Stadhouders, R., Joehrens, K., Wurster, K.D., Callen, D.F., Harte, M.F., Giefing, M., Barlow, R., Stein, H., Anagnostopoulos, I., Janz, M., Cockerill, P.N., Siebert, R., Doerken, B., Bonifer, C. and Mathas, S.
Nature Medicine 16 (5): 571-579, 1p following 579. May 2010

C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells.
Pal, R., Janz, M., Galson, D.L., Gries, M., Li, S., Johrens, K., Anagnostopoulos, I., Doerken, B., Mapara, M.Y., Borghesi, L., Kardava, L., Roodman, G.D., Milcarek, C. and Lentzsch, S.
Blood 114 (18): 3890-3898. 29 October 2009

Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma.
Mathas, S., Kreher, S., Meaburn, K.J., Joehrens, K., Lamprecht, B., Assaf, C., Sterry, W., Kadin, M.E., Daibata, M., Joos, S., Hummel, M., Stein, H., Janz, M., Anagnostopoulos, I., Schrock, E., Misteli, T. and Doerken, B.
Proceedings of the National Academy of Sciences of the United States of America 106 (14): 5831-5836. 7 April 2009

Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α.
Lamprecht, B., Kreher, S., Anagnostopoulos, I., Joehrens, K., Monteleone, G., Jundt, F., Stein, H., Janz, M., Doerken, B. and Mathas, S.
Blood 112 (8): 3339-3347. 15 October 2008

Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma.
Jundt, F., Acikgoez, O., Kwon, S.H., Schwarzer, R., Anagnostopoulos, I., Wiesner, B., Mathas, S., Hummel, M., Stein, H., Reichardt, H.M. and Doerken, B.
Leukemia 22 (8): 1587-1594. August 2008

Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis.
Lietz, A., Janz, M., Sigvardsson, M., Jundt, F., Doerken, B. and Mathas, S.
British Journal of Haematology 137 (4): 342-348. May 2007

Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells.
Janz, M., Stuehmer, T., Vassilev, L.T. and Bargou, R.C.
Leukemia 21 (4): 772-779. April 2007

Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe, M., Sebelin-Wulf, K., Beier, C., Lietz, A., Mathas, S., Doerken, B. and Pezzutto, A.
Human Immunology 68 (3): 147-155. March 2007

Reprogramming of B lymphoid cells in human lymphoma pathogenesis.
Janz, M., Doerken, B. and Mathas, S.
Cell Cycle 5 (10): 1057-1061. 15 May 2006

Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.
Sturm, I., Stephan, C., Gillissen, B., Siebert, R., Janz, M., Radetzki, S., Jung, K., Loening, S., Doerken, B. and Daniel, P.T.
Cell Death and Differentiation 13 : 619-627. April 2006

Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells.
Janz, M., Hummel, M., Truss, M., Wollert-Wulf, B., Mathas, S., Joehrens, K., Hagemeier, C., Bommert, K., Stein, H., Doerken, B. and Bargou, R.C.
Blood 107 (6): 2536-2539. 15 March 2006

Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma.
Mathas, S., Janz, M., Hummel, F., Hummel, M., Wollert-Wulf, B., Lusatis, S., Anagnostopoulos, I., Lietz, A., Sigvardsson, M., Jundt, F., Joehrens, K., Bommert, K., Stein, H. and Doerken, B.
Nature Immunology 7 (2): 207-215. February 2006

Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and other peripheral T-cell lymphomas.
Mathas, S., Joehrens, K., Joos, S., Lietz, A., Hummel, F., Janz, M., Jundt, F., Anagnostopoulos, I., Bommert, K., Lichter, P., Stein, H., Scheidereit, C. and Doerken, B.
Blood 106 (13): 4287-4293. 25 August 2005

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas.
Jundt, F., Raetzel, N., Mueller, C., Calkhoven, C.F., Kley, K., Mathas, S., Lietz, A., Leutz, A. and Doerken, B.
Blood 106 : 1801-1807. 1 January 2005

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis.
Koh, K.R., Janz, M., Mapara, M.Y., Lemke, B., Stirling, D., Doerken, B., Zenke, M. and Lentzsch, S.
Blood 105 (10): 3833-3840. 1 January 2005

c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.
Mathas, S., Lietz, A., Anagnostopoulos, I., Hummel, F., Wiesner, B., Janz, M., Jundt, F., Hirsch, B., Joehrens-Leder, K., Vornlocher, H.P., Bommert, K., Stein, H. and Doerken, B.
Journal of Experimental Medicine 199 (8): 1041-1052. 19 April 2004

Downregulation of genes involved in DNA repair and differential expression of transcription regulators and phosphatases precede IgM-induced apoptosis in the Burkitt's lymphoma cell line BL60-2.
Schories, B., Janz, M., Doerken, B. and Bommert, K.
Biochimica et Biophysica Acta - Gene Structure and Expression 1676 (1): 83-95. 1 January 2004

Jagged1-induced notch signaling drives proliferation of multiple myeloma cells.
Jundt, F., Schulze-Proebsting, K., Anagnostopoulos, I., Muehlinghaus, G., Chatterjee, M., Mathas, S., Bargou, R.C., Manz, R., Stein, H. and Doerken, B.
Blood 103 (9): 3511-3515. 1 January 2004

Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis.
Mathas, S., Lietz, A., Janz, M., Hinz, M., Jundt, F., Scheidereit, C., Bommert, K. and Doerken, B.
Blood 102 (3): 1028-1034. 1 August 2003

Macrophage inflammatory protein 1-alpha (MIP-1alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells.
Lentzsch, S., Gries, M., Janz, M., Bargou, R., Doerken, B. and Mapara, M.Y.
Blood 101 (9): 3568-3573. 1 May 2003

YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression.
Juerchott, K., Bergmann, S., Stein, U., Walther, W., Janz, M., Manni, I., Piaggio, G., Fietze, E., Dietel, M. and Royer, H.D.
Journal of Biological Chemistry 278 (30): 27988-27996. 1 January 2003

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway.
Chatterjee, M., Hoenemann, D., Lentzsch, S., Bommert, K., Sers, C., Herrmann, P., Mathas, S., Doerken, B. and Bargou, R.C.
Blood 100 (9): 3311-3318. 1 November 2002

Nuclear factor κB-dependent gene expression profiling of Hodgkins disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.
Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Doerken, B., Zenke, M., Stein, H. and Scheidereit, C.
Journal of Experimental Medicine 196 (5): 605-617. 2 September 2002

Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.
Mathas, S., Hinz, M., Anagnostopoulos, L., Krappmann, D., Lietz, A., Jundt, F., Bommert, K., Mechta-Grigoriou, F., Stein, H., Dörken, B. and Scheidereit, C.
EMBO Journal 21 (15): 4104-4113. 1 August 2002

Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.
Jundt, F., Anagnostopoulos, I., Foerster, R., Mathas, S., Stein, H. and Doerken, B.
Blood 99 (9): 3398-3403. 1 May 2002

Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease.
Jundt, F., Kley, K., Anagnostopoulos, I., Schulze-Proebsting, K., Greiner, A., Mathas, S., Scheidereit, C., Wirth, T., Stein, H. and Doerken, B.
Blood 99 (8): 3060-3062. 15 April 2002

Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
Janz, M., Harbeck, N., Dettmar, P., Berger, U., Schmidt, A., Juerchott, K., Schmitt, M. and Royer, H.D.
International Journal of Cancer 97 (3): 278-282. 1 January 2002

Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.
Hinz, M., Loeser, P., Mathas, S., Krappmann, D., Dörken, B. and Scheidereit, C.
Blood 97 (9): 2798-2807. 1 January 2001

Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways.
Mathas, S., Rickers, A., Bommert, K., Doerken, B. and Mapara, M.Y.
Cancer Research 60 (24): 7170-7176. 1 January 2000

Y-box factor YB-1 is associated with the centrosome during mitosis.
Janz, M., Juerchott, K., Karawajew, L. and Royer, H.D.
Gene Function and Disease 1 : 57-59. 1 January 2000

Overexpression of IkappaBalpha without inhibition of NF-kappaB activity and mutations in the IkappaBalpha gene in Reed-Sternberg cells.
Emmerich, F., Meiser, M., Hummel, M., Demel, G., Foss, H.D., Jundt, F., Mathas, S., Krappmann, D., Scheidereit, C., Stein, H. and Dörken, B.
Blood 94 : 3129-3134. 1 November 1999

Regulation des Zellzyklus und therapeutische Implikationen.
Royer, H.D., Grinstein, E. and Janz, M.
Onkologe 5 : 884-890. 1 January 1999

Review

The origins of ALK translocations.
Roukos, V. and Mathas, S.
Frontiers in Bioscience 7 : 260-268. 1 June 2015

Die molekulare Pathogenese des klassischen Hodgkin-Lymphoms [The molecular pathogenesis of classical Hodgkin lymphoma].
Mathas, S., Doerken, B. and Janz, M.
Deutsche Medizinische Wochenschrift 134 (39): 1944-1948. September 2009

The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity.
Mathas, S.
Hematology Oncology Clinics of North America 21 (5): 787-804. October 2007

Letter

The DNA methylation status of the TERT promoter differs between subtypes of mature B-cell lymphomas.
Kouroukli, A.G., Fischer, A., Kretzmer, H., Chteinberg, E., Rajaram, N., Glaser, S., Kolarova, J., Bashtrykov, P., Mathas, S., Drexler, H.G., Ohno, H., Ammerpohl, O., Jeltsch, A., Siebert, R. and Bens, S.
Blood Cancer Journal 13 (1): 98. 26 June 2023

A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior.
Wasilewski, D., Janz, M., Koch, A., Rosenwald, A., Keller, U., Vajkoczy, P., Faust, K., Anagnostopoulos, I. and Radke, J.
Acta Neurologica Belgica 123 (2): 667-670. April 2022

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
Damaschin, C., Goergen, H., Kreissl, S., Plütschow, A., Breywisch, F., Mathas, S., Meissner, J., Sökler, M., Topp, M.S., Vucinic, V., Zimmermann, A., von Tresckow, B., Fuchs, M., Engert, A., Borchmann, P. and Eichenauer, D.A.
Leukemia 36 (2): 580-582. February 2022

High-dose glucocorticoid treatment of near-fatal Bocavirus lung infection results in rapid recovery.
Obenaus, M., Schildgen, O., Schürmann, D., von Brünneck, A.C., Janz, M., Keller, U., Gebauer, B., Schilling, J., Schwartz, S., Weissbrich, B., Schneider, T., Hofmann, J. and Mathas, S.
ERJ Open Research 7 (2): 00060-2021. 12 April 2021

The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells.
Ullrich, K., Blumenthal-Barby, F., Lamprecht, B., Koechert, K., Lenze, D., Hummel, M., Mathas, S., Doerken, B. and Janz, M.
Leukemia 29 (5): 1213-1218. May 2015

BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.
Ullrich, K., Wurster, K.D., Lamprecht, B., Koechert, K., Engert, A., Doerken, B., Janz, M. and Mathas, S.
British Journal of Haematology 155 (3): 398-402. November 2011

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation.
Schwarzer, R., Kaiser, M., Acikgoez, O., Heider, U., Mathas, S., Preissner, R., Sezer, O., Doerken, B. and Jundt, F.
Leukemia 22 (12): 2273-2277. December 2008

Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma.
Martin-Subero, J.I., Wlodarska, I., Bastard, C., Picquenot, J.M., Hoeppner, J., Giefing, M., Klapper, W., Siebert, R., Mathas, S., Joos, S., Stein, H. and Doerken, B.
Blood 108 : 401-403. 1 July 2006

Editorial

Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB!
Kreher, S., Cauchy, P., Bonifer, C. and Mathas, S.
Cytokine 72 (1): 115-117. March 2015

The dangers of transcription.
Mathas, S. and Misteli, T.
Cell 139 (6): 1047-1049. 11 December 2009

The pathogenesis of classical Hodgkin's lymphoma: what can we learn from analyses of genomic alterations in Hodgkin and Reed-Sternberg cells?
Janz, M. and Mathas, S.
Haematologica 93 (9): 1292-1295. September 2008

Preprint

N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers.
Lueg, G.A., Faronato, M., Gorelik, A., Grocin, A.G., Caamano-Gutierrez, E., Falciani, F., Solari, R., Carr, R., Bell, A.S., Bartlett, E., Hutton, J.A., Llorian-Sopena, M., Chakravarty, P., Brzezicha, B., Janz, M., Garnett, M.J., Calado, D.P. and Tate, E.W.
bioRxiv : 2021.03.20.436222. 20 March 2021

Co-activation of NF-κB and MYC renders cancer cells addicted to IL6 for survival and phenotypic stability.
Barbosa, R.R., Xu, A.Q., D'Andrea, D., Copley, F., Patel, H., Chakravarty, P., Clear, A., Calaminici, M., Janz, M., Zhang, B., Schmidt-Supprian, M., Wang, J., Gribben, J.G., Tooze, R., Fitzgibbon, J., Franzoso, G., Rajewsky, K. and Calado, D.P.
bioRxiv : 2020.04.12.038414. 13 April 2020